{"id":9418,"date":"2015-04-04T10:42:06","date_gmt":"2015-04-04T08:42:06","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=9418"},"modified":"2015-04-13T13:35:25","modified_gmt":"2015-04-13T11:35:25","slug":"prezzo-dei-farmaci-sei-euro-su-dieci-derivano-da-costi-diversi-dalla-ricerca","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/prezzo-dei-farmaci-sei-euro-su-dieci-derivano-da-costi-diversi-dalla-ricerca\/","title":{"rendered":"Price of medicines: six euros out of ten derive from costs other than research"},"content":{"rendered":"<p><em>The myth that health expenditure is high when it represents only 9% of GDP against the 12% of the European average and even 17% in the USA. \u201cThe weight of wholesalers, retailers and tax authorities. The sector has reached the psychological threshold of 1,000 billion in sales worldwide. The Mps study: Italian expenditure below the EU average, at 9% of GDP against 17% for the United States<\/em><\/p>\n<p><a href=\"http:\/\/www.repubblica.it\/economia\/2015\/04\/03\/news\/spesa_farmaci_mondo_mille_miliardi-111133877\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">03 April 2015 \u2013 R.it ECONOMY &amp; Finance<\/span><\/a><\/p>\n<p><strong><img decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.repstatic.it\/content\/nazionale\/img\/2015\/04\/03\/144053674-a77c8905-17ef-47b5-8fba-e33e84fc0dd8.jpg\" alt=\"Prezzo dei farmaci: sei euro su dieci derivano da costi diversi dalla ricerca\" \/>MILAN <\/strong>\u2013 Six euros out of ten of the over-the-counter price of a drug originates from the costs associated with wholesalers, retail sales and the tax authorities. Only a minor share, however important (the 40% of the price), is due to the expenses for research and development and the contributions of the importing activities. It is one of the data that emerges from the Report on the pharmaceutical industry elaborated by the<a href=\"https:\/\/www.mps.it\/NR\/rdonlyres\/DD522941-ABFC-4D27-B85A-0DA7E9BDF26A\/0\/DISTRIBUZIONEFARMACEUTICAapr2015.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Research &amp; Investor Relations Area<\/span> <\/a>of Banca Monte dei Paschi di Siena. The report deals in particular with the formation of drug prices and distribution, a highly structured and widespread segment of economic activity.<\/p>\n<p>It is no coincidence that we speak of an industrial sector among &quot;the most dynamic in the world&quot;, with the market doubling over the last ten years and sales that for the first time &quot;exceeded the psychological threshold of 1,000 billion dollars, in 2014&quot; . Even in Italy, despite the very difficult economic context in 2013, the pharmaceutical sector had grown by just under 6%, with 72% of the entire production destined for export. For Italy, however, there is an average expenditure lower than that of the EU and the USA.<\/p>\n<p>The report also debunks some clich\u00e9s, &quot;such as the myth that health spending is high when it represents only 9% of GDP against the 12% of the European average and even 17% in the USA&quot;. Even the international comparison of drug prices highlights how those practiced in Italy are not high compared to the foreign average: recent studies highlight how the prices of pharmaceutical products in our country are 14.6% lower than the European average. Analyzes of accredited institutions then show that, however, the costs that must be borne by companies to complete the drug approval process have increased by 145% during the last 10 years, an average compound annual growth rate of 8.5%.<\/p>\n<p><img decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/keynesblog.files.wordpress.com\/2012\/08\/spesa-sanita.jpg?w=560&amp;h=269\" alt=\"\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Il mito che la spesa sanitaria sia elevata quando rappresenta solo il 9% del Pil contro il 12% della media europea e addirittura il 17% negli Usa. &#8220;Il peso di grossisti, rivenditori e Fisco. Il settore ha raggiunto la soglia psicologica di 1.000 miliardi di vendite nel mondo. Lo studio Mps: spesa italiana sotto la &hellip;<\/p>","protected":false},"author":4,"featured_media":9423,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[26,79],"class_list":["post-9418","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-primo-piano","tag-spesa-farmaceutica","tag-ssn"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=9418"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/9418\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9423"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=9418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=9418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=9418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}